Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NST 6179 in Healthy Subjects
NCT05181085Phase 1Completed
- Sponsor
- NorthSea Therapeutics
- Start
- Nov 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in intestinal failure-associated liver disease (IFALD) and Parenteral Nutrition Associated Liver Disease (PNALD) (2 arms), sponsored by NorthSea Therapeutics. Primary endpoint: Number of Participants With AEs and SAEs up to 4 weeks. Started Nov 2021; status: completed.
02
Conditions
intestinal failure-associated liver disease (IFALD)Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT05181085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181085.